Artiva Biotherapeutics To Host Event For Discussing Safety, Translational Data For AlloNK In Combination With Anti-cd20 Antibodies Across Autoimmune Diseases
Benzinga Newsdesk 1 year ago
News
Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and
Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, announced today that management will host a virtual event discussing initial safety and translational data for AlloNK® in combination with anti-CD20 antibodies across autoimmune diseases.